NASDAQ · Health care

Adial Pharmaceuticals, Inc. (ADIL)

It posted a net loss of $57.8M. At June 30, 2026 it held $28.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Price

$4.22

-4.96% on the day · September 25, 2026

52-week range $1.31 to $10.75

Market cap

$11.1M

What Adial Pharmaceuticals, Inc. does

Adial Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ADIL.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$7.8M	-$8M	-$11.93	n/a
2024	n/a	-$8.3M	-$13.2M	-$68.01	n/a
2023	n/a	-$6.9M	-$5.1M	-$90.01	n/a
2022	n/a	-$10.9M	-$12.7M	-$317.80	n/a
2021	n/a	-$19.3M	-$19.4M	-$648.06	-$12M
2020	n/a	-$10.9M	-$10.9M	-$542.12	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 13, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 14, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What Adial Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 18, 2026
Additional proxy material DEFA14A
September 18, 2026
Executive or director change 8-K
September 16, 2026
Additional proxy material DEFA14A
September 16, 2026
Material agreement 8-K
August 28, 2026
Shelf registration to sell securities S-3
August 28, 2026
Employee stock plan registration S-8
August 25, 2026
Unregistered share sale 8-K
August 24, 2026
Annual report to shareholders ARS
August 24, 2026
Proxy statement DEF 14A
August 21, 2026
Stock exchange listing notice 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 21, 2026. Insider transactions on SEC

Insider trades

What the people running Adial Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders bought $106.3K worth of shares on the open market in the last 90 days and sold none.

Bought (open market)

$106.3K

last 90 days

Sold

last 90 days

Net bought

39,986

$106.3K

Date	Insider	What	Shares	Price	Value	Filing
July 16, 2026	Coastlands Capital LP10% owner	Boughtindirect	1,233	$2.75	$3.4K	Form 4
July 14, 2026	Coastlands Capital LP10% owner	Boughtindirect	2,000	$2.65	$5.3K	Form 4
July 10, 2026	Coastlands Capital LP10% owner	Boughtindirect	1,700	$2.70	$4.6K	Form 4
July 9, 2026	Coastlands Capital LP10% owner	Boughtindirect	10,053	$2.79	$28K	Form 4
June 29, 2026	Coastlands Capital LP10% owner	Boughtindirect	25,000	$2.60	$65K	Form 4
June 12, 2026	Davidson MattChief Development Officer, Director	Received as pay	232,417	-	-	Form 4
June 11, 2026	Davidson MattChief Development Officer, Director	Received as pay	61,647	-	-	Form 4
June 11, 2026	Davidson MattChief Development Officer, Director	Received as payindirect	3,427	-	-	Form 4
June 11, 2026	Davidson MattChief Development Officer, Director	Received as pay	1,822	-	-	Form 4
June 11, 2026	Davidson MattChief Development Officer, Director	Received as payindirect	101	-	-	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns ADIL

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Coastlands Capital LP13G, passive with 4 related filers	14.22%	373,322	July 1, 2026

Latest filings below 5%: Armistice Capital, LLC 4.99% (May 15, 2026); Mitchell P. Kopin 2.8% (June 23, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

2 insiders reported holding 692,972 shares in total, about $2.9M at the last price.

Holder	Shares	As of
Coastlands Capital LP10% owner	388,308388,308 held indirectly	July 16, 2026
Davidson MattChief Development Officer, Director	304,6645,350 held indirectly	June 12, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about ADIL

What does Adial Pharmaceuticals, Inc. do?

Adial Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ADIL.

Is Adial Pharmaceuticals, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $57.8M.

When did Adial Pharmaceuticals, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 21, 2026.

Similar companies

Compare ADIL with

Compare ADIL with any company

Follow ADIL

Get an email when Adial Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ADIL: get an email when it files

Where the numbers come from

Financial figures are the values Adial Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.